Skip to Content

Markets
Technicals
Companies
Earnings
Close-Up
Themes

News

Market and company headlines

CTMXAll

Loading

A personal project for following the US markets. Free, ad-free and open source.

Weekly Recap

Every Sunday morning: the week's earnings behind you and the calendar ahead, in one email.

Get It by Email

Market

Markets
Companies
Stock Screener
Macro
Earnings
Technical Analysis
Calendar
Compare
Thematic Lists
Famous Investors

Reading

Guide
Close-Up
Community
News
Brief Archive
Glossary
Tax Calculator
RSS

Account

Watchlist
My Posts
Bell Report
Portfolio
Settings
Privacy

© 2026 Opening BellPrivacy About What's New ContactNot Investment AdviceAhmet Akyapı

Markets Earnings Close-Up Menu

Nasdaq 100 · QQQ720.98+ 1.23%S&P 500 · SPY769.95+ 0.60%Dow Jones · DIA523.16+ 0.04%Russell 2000 · IWM280.18+ 1.15%

CytomX Therapeutics, Inc. (CTMX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
CytomX Therapeutics, Inc. (CTMX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 1:50 PM EDTCompany ParticipantsChris Ogden -...
SeekingAlpha14:01Last MonthCTMX+2.9%

15:00Sep 101 Story

CytomX Therapeutics, Inc. (CTMX) Presents at Wells Fargo 21st Annual Healthcare Conference - Slideshow
2026-09-10. The following slide deck was published by CytomX Therapeutics, Inc.
SeekingAlpha15:09CTMX+2.9%

07:00Aug 131 Story

JP Morgan Maintains Overweight on CytomX Therapeutics, Lowers Price Target to $11
JP Morgan analyst Anupam Rama maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and lowers the price target from $12 to $11.
Benzinga07:25CTMX+2.9%

12:00Aug 121 Story

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway
CTMX stock outlook: PROBODY platform, Varseta-M colorectal cancer data, and catalysts through 1H2027 plus expanded Regeneron deal. Click here to read.
SeekingAlpha12:24CTMX+2.9%

06:00Aug 101 Story

Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14
Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and lowers the price target from $15 to $14.
Benzinga06:13CTMX+2.9%

01:00Aug 71 Story

CytomX Therapeutics Inc (CTMX) (Q2 2026) Earnings Call Highlights: Varetta M Advances Toward ...
Strong clinical progress and expanded Regeneron collaboration bolster CytomX's path forward despite revenue decline and safety considerations.
Yahoo01:03CTMX+2.9%

20:00-22:00Aug 62 Stories

CytomX Therapeutics Q2 Earnings Call Highlights
CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv
Yahoo21:03CTMX+2.9%
CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates
Cytomx (CTMX) shares fell ~30% after Q2 revenue and EPS missed estimates. Lead program Varseta-M Phase 1 data expected by end of 2026.
ChartMill20:02CTMX+2.9%

18:00-20:00Aug 62 Stories

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of +18.18% and -80.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo19:10CTMX+2.9%
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript
CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call August 6, 2026 5:00 PM EDTCompany ParticipantsChris Ogden - SVP, CFO & SecretarySean McCarthy -...
SeekingAlpha18:44CTMX+2.9%